{
    "xml": "<topic id=\"PHP3072\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/pergolide\" basename=\"pergolide\" title=\"PERGOLIDE\">\n<title>PERGOLIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_659\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/pergolide\">Pergolide</xref>\n</p>\n<data name=\"vtmid\">108468004</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_157437168\" title=\"Dopamine receptor agonists\">Dopamine receptor agonists</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP64402\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/pergolide\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Monotherapy in Parkinson's disease where dopamine-receptor agonists other than ergot derivative not appropriate</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 50&#8239;micrograms once daily for day 1, dose to be taken at bedtime, then 50&#8239;micrograms twice daily for days 2&#8211;4, then increased in steps of 100&#8211;250&#8239;micrograms daily, dose to be increased at intervals of 3&#8211;4 days, increased to 1.5&#8239;mg daily in 3 divided doses at day 28, then increased in steps of up to 250&#8239;micrograms every 3&#8211;4&#8239;days, this increase to be started after day 30; maintenance 2.1&#8211;2.5&#8239;mg daily; maximum 3&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjunctive therapy with co-beneldopa or co-careldopa in Parkinson's disease where dopamine-receptor agonists other than ergot derivative not appropriate</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 50&#8239;micrograms daily for 2 days, then increased in steps of 100&#8211;150&#8239;micrograms every 3&#8239;days, dose to be adjusted over next 12 days following initial dose and usually given in 3 divided doses, then increased in steps of 250&#8239;micrograms every 3&#8239;days, during pergolide titration, levodopa dose may be reduced cautiously; maximum 3&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64457\" outputclass=\"importantSafetyInformation\" rev=\"1.11\" parent=\"/drugs/pergolide\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Fibrotic reactions</p>\n<p>Pergolide has been associated with pulmonary, retroperitoneal, and pericardial fibrotic reactions.</p>\n<p>Exclude cardiac valvulopathy with echocardiography before starting treatment with pergolide; it may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine and to obtain a chest X-ray. Patients should be monitored for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal pain or tenderness. If long-term treatment is expected, then lung-function tests may also be helpful. Patients taking pergolide should be regularly monitored for cardiac fibrosis by echocardiography (within 3&#8211;6 months of initiating treatment and subsequently at 6&#8211;12 month intervals).</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Impulse control disorders</p>\n<p>Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist or levodopa should be withdrawn or the dose reduced until the symptoms resolve.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64482\" outputclass=\"contraindications\" rev=\"1.10\" parent=\"/drugs/pergolide\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Cardiac valvulopathy (exclude before treatment)</ph>; <ph outputclass=\"contraindication\">history of fibrotic disorders</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64518\" outputclass=\"cautions\" rev=\"1.17\" parent=\"/drugs/pergolide\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<p>\r\n<ph outputclass=\"caution\">\r\n<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>; <ph outputclass=\"caution\">arrhythmias</ph>; <ph outputclass=\"caution\">dyskinesia (may exacerbate)</ph>; <ph outputclass=\"caution\">hallucinations</ph>; <ph outputclass=\"caution\">history of confusion</ph>; <ph outputclass=\"caution\">psychosis</ph>; <ph outputclass=\"caution\">underlying cardiac disease</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP64391\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/pergolide\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (pergolide).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64286\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/pergolide\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">atrial premature contractions</ph>; <ph outputclass=\"sideEffect\">compulsive behaviour</ph>; <ph outputclass=\"sideEffect\">confusion</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">diplopia</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">dyskinesia</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">erythromelalgia</ph>; <ph outputclass=\"sideEffect\">fever</ph>; <ph outputclass=\"sideEffect\">hallucinations</ph>; <ph outputclass=\"sideEffect\">hiccups</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">insomnia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">palpitation</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">Raynaud&#8217;s phenomenon</ph>; <ph outputclass=\"sideEffect\">rhinitis</ph>; <ph outputclass=\"sideEffect\">sudden onset of sleep</ph>; <ph outputclass=\"sideEffect\">syncope</ph>; <ph outputclass=\"sideEffect\">tachycardia</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64376\" outputclass=\"pregnancy\" parent=\"/drugs/pergolide\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use only if potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64527\" outputclass=\"breastFeeding\" parent=\"/drugs/pergolide\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>May suppress lactation.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64272\" outputclass=\"treatmentCessation\" rev=\"1.8\" parent=\"/drugs/pergolide\">\n<title>Treatment cessation</title>\n<body>\n<section>\n<sectiondiv>\n<p>Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64362\" outputclass=\"patientAndCarerAdvice\" rev=\"1.10\" parent=\"/drugs/pergolide\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"adviceAroundDrivingAndOtherTasks\">\n<title>Driving and skilled tasks</title>\n<sectiondiv>\n<p outputclass=\"title\">Sudden onset of sleep</p>\n<p>Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.</p>\n<p>Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.</p>\n<p>Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hypotensive reactions</p>\n<p>Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP3072-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/pergolide\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77150\" title=\"Tablet\" namespace=\"/drugs/pergolide/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78531\" namespace=\"/treatment-summaries/parkinsons-disease-and-related-disorders\" title=\"Parkinson&#8217;s disease and related disorders\" count=\"1\" rel=\"backlink\">Parkinson&#8217;s disease and related disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_659\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/pergolide\" title=\"Pergolide\" count=\"1\" rel=\"link\">Pergolide</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77150\" namespace=\"/drugs/pergolide/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP3072",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/pergolide",
    "basename": "pergolide",
    "title": "PERGOLIDE",
    "interactants": [
        {
            "id": "bnf_int_659",
            "label": "Pergolide"
        }
    ],
    "vtmid": "108468004",
    "drugClassification": [
        "Dopamine receptor agonists"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Monotherapy in Parkinson's disease where dopamine-receptor agonists other than ergot derivative not appropriate",
                        "html": "Monotherapy in Parkinson's disease where dopamine-receptor agonists other than ergot derivative not appropriate"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 50 micrograms once daily for day 1, dose to be taken at bedtime, then 50 micrograms twice daily for days 2&#8211;4, then increased in steps of 100&#8211;250 micrograms daily, dose to be increased at intervals of 3&#8211;4 days, increased to 1.5 mg daily in 3 divided doses at day 28, then increased in steps of up to 250 micrograms every 3&#8211;4 days, this increase to be started after day 30; maintenance 2.1&#8211;2.5 mg daily; maximum 3 mg per day.",
                        "html": "<p>Initially 50&#8239;micrograms once daily for day 1, dose to be taken at bedtime, then 50&#8239;micrograms twice daily for days 2&#8211;4, then increased in steps of 100&#8211;250&#8239;micrograms daily, dose to be increased at intervals of 3&#8211;4 days, increased to 1.5&#8239;mg daily in 3 divided doses at day 28, then increased in steps of up to 250&#8239;micrograms every 3&#8211;4&#8239;days, this increase to be started after day 30; maintenance 2.1&#8211;2.5&#8239;mg daily; maximum 3&#8239;mg per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Adjunctive therapy with co-beneldopa or co-careldopa in Parkinson's disease where dopamine-receptor agonists other than ergot derivative not appropriate",
                        "html": "Adjunctive therapy with co-beneldopa or co-careldopa in Parkinson's disease where dopamine-receptor agonists other than ergot derivative not appropriate"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 50 micrograms daily for 2 days, then increased in steps of 100&#8211;150 micrograms every 3 days, dose to be adjusted over next 12 days following initial dose and usually given in 3 divided doses, then increased in steps of 250 micrograms every 3 days, during pergolide titration, levodopa dose may be reduced cautiously; maximum 3 mg per day.",
                        "html": "<p>Initially 50&#8239;micrograms daily for 2 days, then increased in steps of 100&#8211;150&#8239;micrograms every 3&#8239;days, dose to be adjusted over next 12 days following initial dose and usually given in 3 divided doses, then increased in steps of 250&#8239;micrograms every 3&#8239;days, during pergolide titration, levodopa dose may be reduced cautiously; maximum 3&#8239;mg per day.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Fibrotic reactions",
                "textContent": "Pergolide has been associated with pulmonary, retroperitoneal, and pericardial fibrotic reactions.\n\nExclude cardiac valvulopathy with echocardiography before starting treatment with pergolide; it may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine and to obtain a chest X-ray. Patients should be monitored for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal pain or tenderness. If long-term treatment is expected, then lung-function tests may also be helpful. Patients taking pergolide should be regularly monitored for cardiac fibrosis by echocardiography (within 3&#8211;6 months of initiating treatment and subsequently at 6&#8211;12 month intervals).",
                "html": "<p>Pergolide has been associated with pulmonary, retroperitoneal, and pericardial fibrotic reactions.</p><p>Exclude cardiac valvulopathy with echocardiography before starting treatment with pergolide; it may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine and to obtain a chest X-ray. Patients should be monitored for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal pain or tenderness. If long-term treatment is expected, then lung-function tests may also be helpful. Patients taking pergolide should be regularly monitored for cardiac fibrosis by echocardiography (within 3&#8211;6 months of initiating treatment and subsequently at 6&#8211;12 month intervals).</p>"
            },
            {
                "type": "importantSafetyInformation",
                "title": "Impulse control disorders",
                "textContent": "Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist or levodopa should be withdrawn or the dose reduced until the symptoms resolve.",
                "html": "<p>Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist or levodopa should be withdrawn or the dose reduced until the symptoms resolve.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Cardiac valvulopathy (exclude before treatment)",
                "html": "Cardiac valvulopathy (exclude before treatment)"
            },
            {
                "type": "contraindications",
                "textContent": "history of fibrotic disorders",
                "html": "history of fibrotic disorders"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Acute porphyrias",
                "html": "<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            },
            {
                "type": "cautions",
                "textContent": "arrhythmias",
                "html": "arrhythmias"
            },
            {
                "type": "cautions",
                "textContent": "dyskinesia (may exacerbate)",
                "html": "dyskinesia (may exacerbate)"
            },
            {
                "type": "cautions",
                "textContent": "hallucinations",
                "html": "hallucinations"
            },
            {
                "type": "cautions",
                "textContent": "history of confusion",
                "html": "history of confusion"
            },
            {
                "type": "cautions",
                "textContent": "psychosis",
                "html": "psychosis"
            },
            {
                "type": "cautions",
                "textContent": "underlying cardiac disease",
                "html": "underlying cardiac disease"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (pergolide).",
                "html": "<p>Appendix 1 (pergolide).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "atrial premature contractions",
                        "html": "atrial premature contractions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "compulsive behaviour",
                        "html": "compulsive behaviour",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "confusion",
                        "html": "confusion",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "diplopia",
                        "html": "diplopia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dyskinesia",
                        "html": "dyskinesia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "erythromelalgia",
                        "html": "erythromelalgia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fever",
                        "html": "fever",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hallucinations",
                        "html": "hallucinations",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hiccups",
                        "html": "hiccups",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "insomnia",
                        "html": "insomnia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "palpitation",
                        "html": "palpitation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "Raynaud&#8217;s phenomenon",
                        "html": "Raynaud&#8217;s phenomenon",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rhinitis",
                        "html": "rhinitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "sudden onset of sleep",
                        "html": "sudden onset of sleep",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "syncope",
                        "html": "syncope",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tachycardia",
                        "html": "tachycardia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use only if potential benefit outweighs risk.",
                "html": "<p>Use only if potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "May suppress lactation.",
                "html": "<p>May suppress lactation.</p>"
            }
        ]
    },
    "treatmentCessation": {
        "treatmentCessation": [
            {
                "type": "treatmentCessation",
                "textContent": "Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.",
                "html": "<p>Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundDrivingAndOtherTasks": [
            {
                "type": "adviceAroundDrivingAndOtherTasks",
                "title": "Sudden onset of sleep",
                "textContent": "Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.\n\nPatients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.\n\nManagement of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.",
                "html": "<p>Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.</p><p>Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.</p><p>Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.</p>"
            },
            {
                "type": "adviceAroundDrivingAndOtherTasks",
                "title": "Hypotensive reactions",
                "textContent": "Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.",
                "html": "<p>Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77150",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78531",
                "label": "Parkinson&#8217;s disease and related disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_659",
                "label": "Pergolide",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77150",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}